{"id":3421,"date":"2022-07-28T17:34:26","date_gmt":"2022-07-28T15:34:26","guid":{"rendered":"https:\/\/www.biopole-clermont.com\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/"},"modified":"2022-07-28T17:39:41","modified_gmt":"2022-07-28T15:39:41","slug":"valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete","status":"publish","type":"breves","link":"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/","title":{"rendered":"Valbiotis announces completion of recruitment for the Phase II\/III REVERSE-IT clinical study with TOTUM\u202263 against prediabetes."},"featured_media":3419,"template":"","class_list":["post-3421","breves","type-breves","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valbiotis announces completion of recruitment for the Phase II\/III REVERSE-IT clinical study with TOTUM\u202263 against prediabetes. - Biop\u00f4le Clermont-Limagne<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valbiotis announces completion of recruitment for the Phase II\/III REVERSE-IT clinical study with TOTUM\u202263 against prediabetes. - Biop\u00f4le Clermont-Limagne\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/\" \/>\n<meta property=\"og:site_name\" content=\"Biop\u00f4le Clermont-Limagne\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-28T15:39:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2022\/07\/Capture-decran-2022-07-28-172457.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"310\" \/>\n\t<meta property=\"og:image:height\" content=\"308\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/\",\"url\":\"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/\",\"name\":\"Valbiotis announces completion of recruitment for the Phase II\/III REVERSE-IT clinical study with TOTUM\u202263 against prediabetes. - Biop\u00f4le Clermont-Limagne\",\"isPartOf\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2022\/07\/Capture-decran-2022-07-28-172457.jpg\",\"datePublished\":\"2022-07-28T15:34:26+00:00\",\"dateModified\":\"2022-07-28T15:39:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/#primaryimage\",\"url\":\"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2022\/07\/Capture-decran-2022-07-28-172457.jpg\",\"contentUrl\":\"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2022\/07\/Capture-decran-2022-07-28-172457.jpg\",\"width\":310,\"height\":308},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.biopole-clermont.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Br\u00e8ves\",\"item\":\"https:\/\/www.biopole-clermont.com\/en\/breves\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Valbiotis announces completion of recruitment for the Phase II\/III REVERSE-IT clinical study with TOTUM\u202263 against prediabetes.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/#website\",\"url\":\"https:\/\/www.biopole-clermont.com\/en\/\",\"name\":\"Biop\u00f4le Clermont-Limagne\",\"description\":\"Technopole des sciences du vivant\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biopole-clermont.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valbiotis announces completion of recruitment for the Phase II\/III REVERSE-IT clinical study with TOTUM\u202263 against prediabetes. - Biop\u00f4le Clermont-Limagne","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/","og_locale":"en_US","og_type":"article","og_title":"Valbiotis announces completion of recruitment for the Phase II\/III REVERSE-IT clinical study with TOTUM\u202263 against prediabetes. - Biop\u00f4le Clermont-Limagne","og_url":"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/","og_site_name":"Biop\u00f4le Clermont-Limagne","article_modified_time":"2022-07-28T15:39:41+00:00","og_image":[{"width":310,"height":308,"url":"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2022\/07\/Capture-decran-2022-07-28-172457.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/","url":"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/","name":"Valbiotis announces completion of recruitment for the Phase II\/III REVERSE-IT clinical study with TOTUM\u202263 against prediabetes. - Biop\u00f4le Clermont-Limagne","isPartOf":{"@id":"https:\/\/www.biopole-clermont.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/#primaryimage"},"image":{"@id":"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2022\/07\/Capture-decran-2022-07-28-172457.jpg","datePublished":"2022-07-28T15:34:26+00:00","dateModified":"2022-07-28T15:39:41+00:00","breadcrumb":{"@id":"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/#primaryimage","url":"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2022\/07\/Capture-decran-2022-07-28-172457.jpg","contentUrl":"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2022\/07\/Capture-decran-2022-07-28-172457.jpg","width":310,"height":308},{"@type":"BreadcrumbList","@id":"https:\/\/www.biopole-clermont.com\/en\/breves\/valbiotis-a-acheve-le-recrutement-de-letude-clinique-de-phase-ii-iii-reverse-it-avec-totum63-contre-le-prediabete\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.biopole-clermont.com\/en\/"},{"@type":"ListItem","position":2,"name":"Br\u00e8ves","item":"https:\/\/www.biopole-clermont.com\/en\/breves\/"},{"@type":"ListItem","position":3,"name":"Valbiotis announces completion of recruitment for the Phase II\/III REVERSE-IT clinical study with TOTUM\u202263 against prediabetes."}]},{"@type":"WebSite","@id":"https:\/\/www.biopole-clermont.com\/en\/#website","url":"https:\/\/www.biopole-clermont.com\/en\/","name":"Biop\u00f4le Clermont-Limagne","description":"Technopole des sciences du vivant","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biopole-clermont.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/breves\/3421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/breves"}],"about":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/types\/breves"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/media\/3419"}],"wp:attachment":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/media?parent=3421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}